Depomed announced that it is currently engaged in settlement discussions with Purdue Pharma in connection with ongoing patent infringement litigation between the company and Purdue. As the order issued by the Court indicates, the case and any pending motions have been administratively terminated, pending the outcome of such discussions. The Court’s order does not constitute a dismissal with prejudice of the case under the Federal Rules of Civil Procedure. As further indicated in the Court’s order, if settlement cannot be consummated, either party may request that the action be reopened.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.